These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 6251494)
1. Inhibition of platelet aggregation and elevation of cyclic-AMP levels in platelets by 13,14-dehydro PGI2 methyl ester. Malmsten C; Claesson HE; Fried J Prostaglandins Med; 1980 Jun; 4(6):453-63. PubMed ID: 6251494 [TBL] [Abstract][Full Text] [Related]
2. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways. Krishnamurthi S; Westwick J; Kakkar VV Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666 [TBL] [Abstract][Full Text] [Related]
3. Prostacyclin (PGI2) inhibits the development in human platelets of ADP and arachidonic acid-induced shape change and procoagulant activity. Ehrman ML; Jaffe EA Prostaglandins; 1980 Dec; 20(6):1103-16. PubMed ID: 7010448 [TBL] [Abstract][Full Text] [Related]
4. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin. Beretz A; Stierle A; Anton R; Cazenave JP Biochem Pharmacol; 1982 Nov; 31(22):3597-600. PubMed ID: 6295405 [TBL] [Abstract][Full Text] [Related]
5. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent. Miller OV; Aiken JW; Shebuski RJ; Gorman RR Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513 [TBL] [Abstract][Full Text] [Related]
6. Effect of prostacyclin on platelet-activating factor induced rabbit and platelet aggregation. Bussolino F; Camussi G Prostaglandins; 1980 Nov; 20(5):781-91. PubMed ID: 6258196 [TBL] [Abstract][Full Text] [Related]
7. Effect of heparin on platelet aggregation inhibited by PGI2, trifluoperazine and verapamil. Weber DR; Nichols WK; Mohammad SF Thromb Res; 1986 May; 42(4):477-87. PubMed ID: 3012821 [TBL] [Abstract][Full Text] [Related]
8. The effects of continuous infusions of prostacyclin-Na (epoprostenol-sodium) on platelet counts, ADP-induced aggregation, and cyclic AMP levels in normal volunteers. Reele SB; Miller OV; Spillers C; Gorman RR Prostaglandins; 1983 Aug; 26(2):287-302. PubMed ID: 6316420 [TBL] [Abstract][Full Text] [Related]
9. Potentiation of anti-aggregating activity of PGI2 by 7-ethoxycarbonyl-6,8-dimethyl-4-hydroxymethyl-1(2H)-phthalazinone (EG-626) in rabbit platelets in vitro. Tanaka K; Harada Y; Iwata M; Katori M Prostaglandins; 1980 Aug; 20(2):255-68. PubMed ID: 6997930 [TBL] [Abstract][Full Text] [Related]
10. The influence of epinephrine on prostacyclin (PGI2) induced dissociation of ADP aggregated plateletes. Rao GH; Reddy KR; White JG Prostaglandins Med; 1980 Jun; 4(6):385-97. PubMed ID: 6251492 [TBL] [Abstract][Full Text] [Related]
11. 6-Keto-prostaglandin E1 inhibits the aggregation of human platelets. Wong PY; McGiff JC; Sun FF; Lee WH Eur J Pharmacol; 1979 Dec; 60(2-3):245-8. PubMed ID: 393526 [TBL] [Abstract][Full Text] [Related]
12. Intracellular levels of cyclic AMP and cyclic GMP differentially modify platelet aggregate size in human platelets activated with epinephrine or ADP. Qi R; Ozaki Y; Satoh K; Yang LB; Asazuma N; Yatomi Y; Kume S J Cardiovasc Pharmacol; 1996 Aug; 28(2):215-22. PubMed ID: 8856476 [TBL] [Abstract][Full Text] [Related]
13. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). Cox CP; Linden J; Said SI Peptides; 1984; 5(2):325-8. PubMed ID: 6206481 [TBL] [Abstract][Full Text] [Related]
14. Reduced platelet aggregation by effects of pentoxifylline on vascular prostacyclin isomerase and platelet cyclic AMP. Weithmann KU Gen Pharmacol; 1983; 14(1):161-2. PubMed ID: 6298055 [TBL] [Abstract][Full Text] [Related]
15. In vitro effects of ethanol on rabbit platelet aggregation, secretion of granule contents, and cyclic AMP levels in the presence of prostacyclin. Rand ML; Gross PL; Jakowec DM; Packham MA; Mustard JF Thromb Haemost; 1989 Apr; 61(2):254-8. PubMed ID: 2546284 [TBL] [Abstract][Full Text] [Related]
16. A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man. O'Grady J; Hedges A; Whittle BJ; Al-Sinawi LA; Mekki QA; Burke C; Moody SG; Moti MJ; Hassan S Br J Clin Pharmacol; 1984 Dec; 18(6):921-33. PubMed ID: 6085004 [TBL] [Abstract][Full Text] [Related]
17. Refractoriness of platelets to prostaglandins after infusion in rabbits. Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353 [TBL] [Abstract][Full Text] [Related]
18. Benzodiazepines inhibit human platelet activation: comparison of the mechanism of antiplatelet actions of flurazepam and diazepam. Romstedt K; Huzoor-Akbar Thromb Res; 1985 May; 38(4):361-74. PubMed ID: 2990062 [TBL] [Abstract][Full Text] [Related]
19. Effects of dipyridamole in experimental atherosclerosis. Action on PGI2, platelet aggregation and atherosclerotic plaque formation. Dembińska-Kièć A; Rücker W; Schönhöfer PS Atherosclerosis; 1979 Jul; 33(3):315-27. PubMed ID: 226106 [TBL] [Abstract][Full Text] [Related]
20. Effect of prostacyclin (epoprostenol) on the aggregation of human platelets in whole blood in vitro. Saniabadi AR; Lowe GD; Belch JJ; Barbenel JC; Forbes CD Haemostasis; 1984; 14(6):487-94. PubMed ID: 6442909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]